載入中
NASDAQHealthcareBiotechnology
最新資料
US$3.85
+US$0.24 · +6.65%
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
前收盤價
US$3.85
+US$0.24 · +6.65%
盤後
US$3.84
−US$0.01 · -0.26%
10月12日 下午7:52 ET
盤中時間採用ET。市場資料可能有所延遲。
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
日內區間
目前US$3.85
52週區間
目前US$3.85
盤中時間採用ET。市場資料可能有所延遲。
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
日內區間
目前US$3.85
52週區間
目前US$3.85
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 123.4萬 USD | 13.5萬 USD | — | — | — |
| 銷貨成本 | 5.3萬 USD | — | — | — | — |
| 毛利 | 118.1萬 USD | 13.5萬 USD | — | — | — |
| 研究與開發 | 751.8萬 USD | 910.5萬 USD | 597.3萬 USD | 250.3萬 USD | 276.6萬 USD |
| 銷售、一般及管理費用 | 583.8萬 USD | 887.2萬 USD | 803.7萬 USD | 691.6萬 USD | 168.3萬 USD |
| 營業費用 | 1335.6萬 USD | 1797.7萬 USD | 1421萬 USD | 1160.9萬 USD | 444.9萬 USD |
| 利息收入 | 32.5萬 USD | 10.1萬 USD | — | 630 USD | — |
| 利息支出 | 32.9萬 USD | 24.4萬 USD | 108.1萬 USD | 63萬 USD | 21.2萬 USD |
| 折舊和攤銷 | 1.8萬 USD | — | 1401萬 USD | — | — |
| 營業利益 | −1217.5萬 USD | −1784.2萬 USD | −1421萬 USD | −1160.9萬 USD | −444.9萬 USD |
| 淨利 | −1215萬 USD | −2483萬 USD | −2623.2萬 USD | −1219萬 USD | −459.6萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月5日 | 1:10 | — | — |
股票分割 | 2024年6月10日 | 1:25 | — | — |
已生效 2026年1月5日
1:10
已生效 2024年6月10日
1:25
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
